Patrick D. Lyden, MD

Carmen and Louis Warschaw Chair in Neurology

Professor, Neurology

Patrick D. Lyden, MD

Neurology - Pavilion
127 S San Vicente Blvd - 6th Floor #A6600
Los AngelesCA
90048

Phone:

310-423-6472

Fax:

310-423-0777

Patrick D. Lyden, MD

Carmen and Louis Warschaw Chair in Neurology

Professor, Neurology

  • Neurology
  • Stroke

Alzheimer's Disease

Amyloidosis

Bell's Palsy

Brain Aneurysms

Brain Hemorrhage

Carotid Artery Diseases

Carpal Tunnel Syndrome

Cervical Myelopathy

Concussions

Dementia

Essential Tremors

Lumbar Puncture

Meningitis

Moya Moya Disease

Postherpetic Neuralgia

Stroke (Cerebrovascular Accident) - CVA

Trigeminal Neuralgia

Vertigo

Vestibular Dysfunction

The research of Patrick D. Lyden, MD, focuses on translational stroke research. One theme involves understanding the role of thrombin in mediating cytotoxicity during ischemia. In collaboration with Roger Tsien at University of California, San Diego and other colleagues, Lyden's research has shown that during a stroke, thrombin enters the brain, adheres to neurons, and kills them via the protease activated receptor (PAR-1). His research has also shown that thrombin inhibitors block this cytotoxicity and ameliorate the behavioral and histological effects of stroke. Recently, Lyden and his colleagues have shown that thrombin inhibitor Argatroban powerfully protects the brain when delayed as late as three hours after stroke. Future studies are aimed at understanding the mechanism by which thrombin enters brain and whether thrombin plays any other roles, such as pre-conditioning. A second theme involves treating stroke with hypothermia. Lyden and his colleagues propose to address critical questions about cooling target-depth, duration, and delay-time window, as well as develop new tools for translational studies in this field. He aims to determine the relationship among target-depth, duration, and delay, and to develop new models for conducting further research into therapeutic hypothermia, considered the most potent putative neuroprotectant available.

  • Internship: Mercy Hospital and Medical Center, 1982
  • Residency: University of California, San Diego School of Medicine, 1985
  • Fellowship: University of California, San Diego School of Medicine, 1987
  • Editorial Board: Stroke, Current
  • Peer Reviewer: Lancet, Current
  • Peer Reviewer: Science Translational Medicine, Current
  • Editorial Board: Therapeutic Hypothermia and Temperature Management, Current
  • Associate Editor: The International Journal of Stroke, Current
  • Chen B, Friedman B, Whitney MA, Winkle JA, Lei IF, Olson ES, Cheng Q, Pereira B, Zhao L, Tsien RY, Lyden PD. Thrombin activity associated with neuronal damage during acute focal ischemia. J Neurosci. 2012;32(22):7622-7631.
  • Chen B, Van Winkle JA, Lyden PD, Brown JH, Purcell NH. PHLPP1 gene deletion protects the brain from ischemic injury. J Cereb Blood Flow Metab. 2012;33(2):196-204.
  • Lyden P, Pereira B, Chen B, Zhao L, Lamb J, Lei IF, Rajput P. Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models. Stroke. 2014;45(3):896-899.

English

Make an Appointment

Call

1-800-CEDARS-1

(1-800-233-2771)

Available 24 Hours A Day

or

Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.